Oral Lichen Planus Successfully Treated With Upadacitinib
Journal of Drugs in Dermatology · 2024
DOI: 10.36849/jdd.7859 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Drugs in Dermatology, 2024. Verfasst von Kristin Slater und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Lichen Planus, Oral, Janus Kinase Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref).
Abstract (Originalsprache)
With the rise of Janus kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) inhibitor use in dermatologic conditions, there has been increasing hope in treating extensive and difficult-to-treat inflammatory cutaneous conditions. Today we report a case of oral lichen planus successfully treated with an oral JAK1 inhibitor, upadacitinib. This case had been unresponsive by several standard methods but responded with 70% improvement within 1 month when treated with upadacitinib. J Drugs Dermatol. 2024;23(4):7859. doi:10.36849/JDD.7859e .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Slater, K., Halash, K., & Kartono, F. (2024). Oral Lichen Planus Successfully Treated With Upadacitinib. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.7859
Vancouver
Slater K, Halash K, Kartono F. Oral Lichen Planus Successfully Treated With Upadacitinib. Journal of Drugs in Dermatology. 2024. doi:10.36849/jdd.7859
BibTeX
@article{Slater2024,
author = {Slater, Kristin and Halash, Katelyn and Kartono, Francisca},
title = {Oral Lichen Planus Successfully Treated With Upadacitinib},
journal = {Journal of Drugs in Dermatology},
year = {2024},
doi = {10.36849/jdd.7859}
}
EUVIMED